Neelesh Sharma, M.D., Ph.D., is Senior Vice President, Clinical Development at Prelude Therapeutics. Dr. Sharma is a medical oncologist with extensive experience conducting both early and late-stage drug development clinical trials, translational research, formulating strategy, leading teams, monitoring studies, and engaging with senior leaders in academia, industry and health authorities. Prior to joining Prelude, he spent several years at Bayer Pharmaceuticals, first as Senior Clinical Development Leader, Immuno-oncology (Early and Late Phase) and then as Vice President, Head, Precision Oncology (Early Development) where he led early clinical development of the precision oncology/targeted therapies portfolio which includes the Bayer-Broad Institute Collaboration and Bayer-MD Anderson Collaboration for early drug development. Before joining Bayer, Dr. Sharma was Clinical Program Leader (Early Development) at the Novartis Institute of Biomedical Research. Prior to his career in biopharma, he spent five years in academia as an Assistant Professor, Medical Oncology at Roswell Park Cancer Institute (RPCI), Buffalo, NY and then Assistant Professor, Medicine at Case Western Reserve University in Cleveland, Ohio. Dr. Sharma earned his medical degree from G.S.V.M. Medical College in India and a Ph.D. in physiology and pharmacology from The University of Georgia.
A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.